Connect with us
Prague Gaming & TECH Summit 2024

Fintech PR

Epazz Provitrac Develops Video Interviewing Feature for Applicant Tracking System to Meet the Increase in Job Applications Post COVID-19

Published

on

Reading Time: 3 minutes

Provitrac is an excellent business solution to find the perfect candidate to fill in the job vacancy of an organization

Chicago, Illinois–(Newsfile Corp. – August 20, 2020) –  Epazz Inc. (OTC Pink: EPAZ), the parent company of DeskFlex, a leading provider of cloud-based business software solutions, announced today that its Provitrac applicant tracking solution is now developing the Video Interviewing online feature to anticipate the increase in online job applications and work from home applications after COVID-19 lockdowns.

Provitrac is a candidate recruiting software that provides the best features of any other hiring software, including job posting in online media outlets, applicant tracking, candidate ranking, job matching, sorting and scoring, and onboarding management. Provitrac applicant tracking software platform features an integrated client support system, phone system, custom reporting, and the newly added feature of Video Interviewing software.

Hiring managers can use the Provitrac Video Interviewing software to set a job interview with a potential candidate similar to an in-person or phone interview via integration with Zoom videoconferencing. In a large organization that needs massive hiring, Provitrac can also provide an automated video interview that records an applicant’s response to standard preliminary interview questions. With preset screening questions, recruiting officers can immediately filter candidates who do not meet the criteria leaving only the most suitable candidates for a final face-to-face interview.

Provitrac, formerly known as AutoHire software, has been operating in small and large Fortune 500 companies, government agencies, and the private sector since 2002. Epazz, Inc acquired AutoHire Software in 2010 and later renamed it to Provitrac in 2016. The Provitrac applicant tracking system streamlines the hiring process in one web-based platform. It simplifies recruitment, career management, vacancy creation and approval, job posting, job matching, staff acquisition, resume search, resume management, applicant tracking, easy reporting, and communications.

The Provitrac applicant tracking solution integrates well with DeskFlex room scheduling software. With the onset of the COVID pandemic, more organizations allow their employees to work from home and hire remote workers to fill in company vacancies. Reopening the office post-COVID lockdowns can only allow a few staff to come to the office to work. This change in the work dynamics prompts companies to use efficient applicant tracking software to find the best hire and the need for room scheduling software to alternate the schedules between work from home employees and return to office workers to revamp the economy after the economic decline following COVID-19.

According to Shaun Passley, Ph.D., CEO of Epazz, Inc., “We saw the growing need of recruiters to automate the hiring processes. There is a real opportunity to create something more strategic and aligned to the hiring process, especially finding the right candidate for rebuilding the economy after the Coronavirus pandemic.”

About Provitrac.com

Provitrac is a total cloud-based applicant tracking software that supports online job posting, candidate tracking, and interviews. Provitrac software solutions organize candidate management, automate workflow, and open company communication in an online platform. It provides any business in an easily accessible way to manage the recruiting process with the web-based interface. Provitrac applicant tracking software solutions are customizable according to the organization’s needs for new hires and allow organizations to handle their recruitment solutions electronically. Provitrac applicant tracking system is available in different modules covering each element of the recruitment process and HR management.

About Epazz, Inc. (www.epazz.com)

Epazz, Inc., is a leading cloud-based software company that specializes in providing customized cloud applications to the corporate world, higher-education institutions, and the public sector. Epazz BoxesOS™ v3.0 is a complete web-based software package for small- to mid-size businesses, Fortune 500 enterprises, government agencies, and higher education institutions. BoxesOS provides many of the web-based applications organizations would otherwise need to purchase separately. Epazz’s other products are K9Sky.com kennel software and the Provitrac applicant tracking system.

SAFE HARBOR

This is the “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: certain statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by the use of forward-looking words such as “may,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” and “continue” (or the negation thereof) or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from future results or those implied by such forward-looking statements. Investors are cautioned that no forward-looking statement is a guarantee of future performance and that actual results may differ materially from those contemplated by such forward-looking statements. Epazz, Inc. assumes no obligation and has no intention of updating these forward-looking statements. It has no obligation to update or correct information prepared by third parties that are not paid for by Epazz, Inc. Investors are encouraged to review Epazz, Inc.’s public filings on SEC.gov and otcmarkets.com, including its unaudited and audited financial statements and its OTC market filings, which contain general business information about the company’s operations, results of operations, and risks associated with the company and its services.

CONTACT: For more information, please contact

Investor Relations
[email protected]
(312) 955-8161
www.epazz.com

Powered by WPeMatico

Fintech PR

Asia’s leading tech company to partner with Nagad

Published

on

asia’s-leading-tech-company-to-partner-with-nagad

DHAKA, Bangladesh, March 28, 2024 /PRNewswire/ — Southeast Asia’s first tech billionaire Goh Peng Ooi has expressed his keen interest in partnering with Nagad, a leading mobile financial service provider based in Bangladesh, through his established Silverlake Group that provides financial software and digital services to banks.

The Malaysian fintech mogul first learnt about Nagad, went through relevant case studies, and gave the go-ahead – this will mark Silverlake Group’s first partnership initiative in South Asia.

Recently, Tanvir A. Mishuk, executive chairman and CEO of Nagad Ltd., received a warm invitation from Goh Peng Ooi at his residence in Malaysia. Impressed by Nagad’s customer-friendly innovations, acquisition of over 9 crore customers within just five years, and its unique business model, Goh Peng promptly expressed his interest in making the partnership Nagad. During this courtesy call, Mishuk also invited him to Nagad Ltd.

Founded in 1989, Silverlake Group currently provides support to more than 400 banks operating in over a hundred countries. Almost all banks in Singapore, including its two main banks United Overseas Bank (UOB) and Oversea-Chinese Banking Corporation (OCBC), are heavily dependent on Silverlake’s technology. Its business collaborations extend across Europe, America, Australia, Africa, and Asia.

During the meeting with Tanvir A. Mishuk, Goh Peng Ooi said they had previously received multiple proposals from different companies in various South Asian countries, including Bangladesh and India, but they hadn’t found sufficient reasons to integrate them into Silverlake. However, they perceive Nagad differently in the realm of financial entities.

According to the proposal, Silverlake Group will offer Nagad the opportunity to utilise its most advanced banking technologies. Nagad believes this initiative will not only benefit Nagad but also bring significant changes to the entire banking sector in Bangladesh.

Talking about Goh Peng Ooi and Silverlake Group’s interest in partnering with Nagad, CEO of Nagad Ltd. Tanvir A. Mishuk, said, “I think this is not only good news for Nagad but also for the entire Bangladesh, as it creates the possibility of a massive change in the country’s banking landscape. We believe it will eventually play a transformative role for millions of people in the country.”

Inaugurated by Honourable Prime Minister Sheikh Hasina in 2019 as a mobile financial service, Nagad is now preparing to emerge as the country’s first digital bank in the middle of this year. Nagad has already introduced some ground-breaking innovations, leading to a transformation in the country’s financial industry. Nagad also hopes to continue to better serve its customers through its digital bank.

About Nagad Ltd (https://www.nagad.com.bd/)

Nagad Limited is one of the leading MFS operators in Bangladesh’s payment industry with 90 million registered customers and an average daily transaction of about USD 113 million. The digital payment platform, known as a successful public-private partnership between Bangladesh Postal Department and the private sector.

Contact:
Lincoln Md. Lutforzaman Sarker
Assistant Vice President (AVP),
Media and Communications, Nagad Limited.
Email: [email protected]

Photo – https://mma.prnewswire.com/media/2373134/Nagad_PR_Image.jpg

Logo – https://mma.prnewswire.com/media/1918049/4617364/Nagad_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/asias-leading-tech-company-to-partner-with-nagad-302100783.html

Continue Reading

Fintech PR

Hakluyt’s 2023 accounts record another year of strong growth

Published

on

hakluyt’s-2023-accounts-record-another-year-of-strong-growth

LONDON, March 28, 2024 /PRNewswire/ — Hakluyt, the global strategic advisory firm for businesses and investors, recorded another period of robust financial growth in the year ending 30 June 2023, expanding its core advisory business while investing for the future.

The firm’s financial results, which were filed today with Companies House, show that revenue increased by 9% to a new record level, with a slightly lower profit margin reflecting substantial investment in the firm’s people and geographic footprint. During this period, Hakluyt opened new offices in Abu Dhabi and Toronto, and continued to recruit new talent worldwide.

Hakluyt also announced its first investment fund, Hakluyt Capital, during this period, which gives some of the world’s most promising growth-stage companies access to the firm’s unrivalled global connectivity, advice and expertise.  

Hakluyt’s managing partner, Varun Chandra, said: “As business leaders continue to face increasingly complex challenges, we have invested in the international reach and expertise of our team, which enable us to provide world-class counsel and connectivity where they are most needed. I am pleased that our core business grew substantially in the financial year 2022-23, and that operating profits remained strong. My thanks to every member of the brilliant Hakluyt team who has helped us deliver against our plan.”

Notes to editors:

Hakluyt is a strategic advisory firm that works with corporate leaders and investors around the world on their most important commercial issues. For more information on the firm, please visit www.hakluytandco.com 

 

 

View original content:https://www.prnewswire.co.uk/news-releases/hakluyts-2023-accounts-record-another-year-of-strong-growth-302102488.html

Continue Reading

Fintech PR

Tigermed Reports Full Year 2023 Results

Published

on

tigermed-reports-full-year-2023-results

HANGZHOU, China, March 28, 2024 /PRNewswire/ — Hangzhou Tigermed Consulting Co., Ltd. (“Tigermed” or the “company”) (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2023 (the “Reporting Period”).

This press release is for information and summary only and is not intended to provide any representation, in whole or in part, of the relevant matters. For further information, please refer to the 2023 annual results and relevant announcements published on the websites of the Shenzhen Stock Exchange (www.szse.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk).

All financials disclosed in this press release are prepared based on International Financial Reporting Standards (IFRS) except for those specifically noted otherwise.

The 2023 Annual Results of the Company has been audited.

Financial Highlights:

  • Total revenue achieved 4.2% year-over-year (“YoY”) growth to RMB 7,384 million during the Reporting Period.
  • Adjusted Non-IFRS net profit attributable to the owners of the Company increased by 7.2% YoY to RMB 1,786 million during the Reporting Period.
  • Segment revenue generated from Clinical Trial Solutions reached RMB 4,168.1 million and that from Clinical-related and Lab Services reached RMB 3,215.9 million, representing a YoY growth of 1.0% and 8.6%, respectively.
  • Geographically, China’s revenue increased by 17.6% YoY to RMB 4,234.5 million. The company’s overseas revenue decreased by 9.6% YoY to RMB 3,149.5 million in 2023.

Business Highlights

Tigermed continued to empower pharmaceutical and medical device innovation in 2023 and navigated the complexities of the life science sector, solidifying its leading position in the clinical CRO industry. From 2004 to 2023, Tigermed provided services to 61% of all Class I new drug approvals in China. During the reporting period, Tigermed assisted in the approval of 22 Class I new drugs and 6 innovative medical devices in China. Additionally, Tigermed opened its International Headquarters in Hong Kong in 2023, serving as the main hub for overseas functional support and business development. As of December 31, 2023, Tigermed had 9,701 total employees in 28 countries worldwide, including 1,632 overseas employees.

In the clinical trial solutions field, as of December 31, 2023, Tigermed has 752 ongoing drug clinical trials and 465 ongoing medical device & IVD projects. In 2023, Regulatory Affairs had a total of 1,009 accumulated project experience, added 29 new US FDA IND projects, and assisted 9 products to receive approvals in China. Medical Translation added 86 new customers in 2023. Besides, Medical Device & IVD assisted 6 innovative medical device products to receive China launch approvals. Moreover, Real World Studies projects have been further expanded to multiple therapeutic areas, including oncology, rare diseases, orthopaedics, etc.

In the clinical-related and lab services field, as of December 31, 2023, Tigermed Data Management & Statistical Analysis (“DMSA”) team had over 850 professionals globally, serving a total of 340 customers, with ongoing projects increasing to 826.

In addition, Tigermed Site Management (“SMO”) had 1,952 ongoing SMO projects as of December 31, 2023 and provided services to support 50 Class I innovative drug approvals in China accumulatively. Tigermed’s Clinical Trial Sites of Excellence (“E-Site”) had 224 core collaborative sites and 74 green channel sites. Furthermore, Independent Central Imaging has provided services for over 280 clinical trials, with 25 products approved.

In 2023, Tigermed laboratory services–Frontage, completed the acquisition of Nucro-Technics Holdings, Inc. and its subsidiary, Nucro-Technics, Inc. (“Nucro Technics”), expanding its lab capacity by over 60,000 square feet. Moreover, on June 6, 2023, Frontage Suzhou Safety Assessment Center obtained the GLP (Good Laboratory Practice) certification issued by the NMPA.

In 2023, Tigermed accelerated the integration of innovative and digital technologies into clinical development, introducing a wide range of virtual and hybrid approaches to Decentralized Clinical Trials (DCT). The company’s in-house DCT technology has been widely used in various projects, including pivotal clinical trials, post-marketing studies, real-world studies, etc., covering therapeutic areas including oncology, hematology, central nervous system, respiratory and endocrine, etc.

As of December 31, 2023, 13% of Tigermed’s ongoing clinical trials had adopted the DCT hybrid model. Further, Tigermed played a significant role in the development of China’s DCT ecosystem and published the landmark report on the DCT Industry Best Practice and authored Tigermed DCT Global Regulatory Handbook.

In 2023, Tigermed continued to deepen its global presence and service capabilities. Tigermed US clinical operation business saw rapid growth in revenue and backlog with a well-supported integrated platform and a growing team. Tigermed US team had accumulated know-how from over 100 clinical trials. As of December 31, 2023, Tigermed had 59 ongoing multi-regional clinical trials (MRCTs) conducted in countries across North America, Asia Pacific, Europe, and Africa, as well as 194 ongoing single region overseas clinical trials, primarily in South Korea, Australia, and the United States.

Tigermed’s exceptional performance earned recognition from industry, media outlets, and other stakeholders, including an upgrade to an AA rating by MSCI. Tigermed has also received notable awards, such as being named the Best Medical Device Overseas Enabling Service Provider and LinkedIn Best Employer Brand Award, etc.

Management Comments

“Despite industry fluctuations in 2023, Tigermed maintained a steady growth, reflecting our team’s dedication and the company’s robust capabilities and resilience,” stated Dr. Xiaoping Ye, Co-Founder and Chairman of Tigermed. “Looking ahead, the life science industry remains ripe with vast opportunities and potential. The company will continue to embrace regulatory changes, technological innovation, and global expansion to deliver value to society.”

Dr. Xiaochun Cao, Co-Founder, Executive Director, and President of Tigermed, said: “Since our founding in 2004, Tigermed has been integral to China’s pharmaceutical evolution from imitation to innovation. With global expansion and exceptional quality, we’re driving impactful advancements in clinical research and addressing patient needs for better health outcomes.”

Mr. Hao Wu, Executive Director and Co-President of Tigermed, said: “Tigermed is dedicated to delivering professional, high-quality, and efficient services, actively responding to market changes, and advancing innovative product launches to meet diverse customer needs. Looking forward, Tigermed remains steadfast in its mission, collaborating globally to drive medical industry development and contribute to human health.”

Forward-Looking Statements

The information communicated herein may contain certain “forward-looking statements”, which are not historical facts but instead include predictions about future events based on our beliefs and information currently made available to us. Although we believe that these predictions are reasonable on the date hereof, future events are inherently uncertain and these forward-looking statements may turn out to be incorrect. Forward-looking statements involve risk and uncertainty by nature because they relate to events and will depend on circumstances that will occur in the future relating to, inter alia, our ability to compete effectively, our ability to develop and market new service offerings, our ability to expand into new markets, the risks associated with listed subsidiaries of the Company, unforeseeable international tensions, regulatory or governmental scrutiny in certain countries, the impact of emergencies and other force majeure events. We undertake no obligations to update forward-looking statements or to adapt them to future events or developments except as required by applicable laws or listing rules. Any investment in any securities issued by the Company or its subsidiaries will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, you should not rely on these forward-looking statements.

Non-IFRS Measure

To supplement our financial information which are presented in accordance with IFRS, we use adjusted net profit attributable to owners of the Company as an additional financial measure, which is not required by, or presented in accordance with IFRS. We define adjusted net profit attributable to owners of the Company as profit for the year attributable to owners of the Company before certain expenses and amortization. We define adjusted net profit attributable to owners of the Company as profit attributable to owners of the Company adjusted for (1) share-based compensation expense, (2) net foreign exchange loss/(gain), (3) amortization of intangible assets arising from acquisitions, (4) listing expenses incurred by our Group, and (5) increase in fair value of financial assets at FVTPL. Adjusted net profit attributable to owners of the Company is not an alternative to (i) profit before tax, profit for the year or profit for the year attributable to owners of the Company (as determined in accordance with IFRS) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to meet our cash needs, or (iii) any other measures of performance or liquidity. We believe that this non-IFRS measure is useful for understanding and assessing underlying business performance and operating trends and that the owners of the company and we may benefit from referring to this non-IFRS measure in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that we do not consider indicative of the performance of our business. However, the presentation of this non-IFRS measure is not intended to, and should not, be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS measure on a stand-alone basis or as a substitute for results under the IFRS, or as being comparable to results or a similarly titled financial measure reported or forecasted by other companies.

About Tigermed

Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 2,800 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 9,700 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.

View original content:https://www.prnewswire.co.uk/news-releases/tigermed-reports-full-year-2023-results-302102467.html

Continue Reading

Trending